New and Emerging Antidepressant Strategies in MDD
neuroscienceCME WebcastPremiere Date: Friday, January 22, 2016
This activity offers CE credit for:%>
- Physicians (CME)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Sunday, January 22, 2017
Note: Credit Is No Longer Available
|Alan F. Schatzberg, MD
Kenneth T. Norris, Jr., Professor
Department of Psychiatry and Behavioral Sciences
Stanford University School of Medicine
This video is a replay of a plenary session from the 8th Annual Chair Summit Master Class for Neuroscience Professional Development held in Miami Florida on September 24-26, 2015.
At the end of this CE activity, participants should be able to:
- Initiate a treatment plan that includes the latest pharmacotherapeutic options for the treatment of MDD.
This activity is supported by an educational grant Allergan, Inc.
Physicians, physician assistants, nurse practitioners, and other nonphysician health care professionals with an interest in psychiatry, neurology, and the neurosciences.
CME Credit (Physicians):
CME Credit (Physicians): CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Schatzberg has disclosed:
Research/Grants: Pritzker Foundation
Consultant: Lundbeck/Takeda Pharmaceuticals U.S.A., Inc.; Myriad Genetics, Inc.; Naurex Inc.; Neuronetics Inc.; One Carbon; Pfizer Inc.
Stockholder: Amnestix, Inc.; Cervel Neurotech, Inc.; Corcept Therapeutics; Merck & Co., Inc.; Pfizer Inc.; Titan pharmaceuticals, Inc.; Xhale, Inc.
Other Financial Interest: American Psychiatric Association (Royalties); Stanford University (Royalties)
Disclosures were obtained from the CME Outfitters, LLC staff: Nothing to Disclose
Howard Bliwise, MD (peer reviewer) has no disclosures to report.
Robert Kennedy (planning committee) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).